The estimated Net Worth of Albert N Ii Marchio is at least $118 ezer dollars as of 29 August 2017. Mr Marchio owns over 2,500 units of Brickell Biotech Inc stock worth over $7,898 and over the last 21 years he sold BBI stock worth over $110,390.
Sign up
Mr II BBI stock SEC Form 4 insiders trading
Mr has made over 4 trades of the Brickell Biotech Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 3,361 units of BBI stock worth $33,610 on 22 November 2017.
The largest trade he's ever made was selling 3,361 units of Brickell Biotech Inc stock on 22 November 2017 worth over $33,610. On average, Mr trades about 682 units every 400 days since 2003. As of 29 August 2017 he still owns at least 3,361 units of Brickell Biotech Inc stock.
You can see the complete history of Mr Marchio stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Albert Nicholas Marchio II biography
Albert Nicholas Marchio II is the Chief Financial Officer at Brickell Biotech Inc.
How old is Mr II?
Mr II is 69, he's been the Chief Financial Officer of Brickell Biotech Inc since . There are no older and 17 younger executives at Brickell Biotech Inc.
What's Mr II's mailing address?
Albert's mailing address filed with the SEC is 5777 CENTRAL AVENUE, SUITE 102, , BOULDER, CO, 80301.
Insiders trading at Brickell Biotech Inc
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi és Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
What does Brickell Biotech Inc do?
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
What does Brickell Biotech Inc's logo look like?
Complete history of Mr Marchio stock trades at Alio Gold és Brickell Biotech Inc
Brickell Biotech Inc executives and stock owners
Brickell Biotech Inc executives and other stock owners filed with the SEC include:
-
Vijay Samant,
Director -
Attorney Robert Busard Brown,
CEO & Director -
Deepak Chadha,
Chief R&D Officer -
Reginald L. Hardy M.B.A., R.Ph.,
Co-Founder & Chairman -
Dennison Veru,
Director -
Gary Lyons,
Director -
Adam Levy,
Chief Business Officer -
Deepak Chadha,
Chief Research and Development Officer -
David McAvoy,
Chief Compliance Officer, General Counsel, Assistant Secretary -
Jose Breton,
Chief Accounting Officer, Controller -
R. Carruthers,
Chief Financial Officer -
Andrew Sklawer,
Co-Founder, Chief Operating Officer, Secretary -
Robert Brown,
Chief Executive Officer, Director -
Reginald Hardy,
Chairman of the Board, Co-Founder -
Sue Fattor,
Head of Human Resource -
Aron Aizenstat M.B.A., P.M.P.,
VP of Corp. Devel. & Operations -
Gary S. Walker,
Chief Marketing Officer -
David R. Mcavoy J.D.,
Gen. Counsel & Chief Compliance Officer -
Jose Breton,
Controller & Chief Accounting Officer -
Albert Nicholas Marchio II,
Chief Financial Officer -
Sanjeev Ahuja,
Chief Medical Officer -
George B Abercrombie,
CHIEF EXECUTIVE OFFICER -
Monica E. Luchi,
Chief Medical Officer -
Albert N Ii Marchio,
Chief Financial Officer